We are live on ! Find out more
CEROW

CERo Therapeutics Warrants
CEROW

Delisted

CEROW was delisted on the 30th of October, 2025.

Back to rankings

1 hedge funds and large institutions have $4 invested in CERo Therapeutics Warrants in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

64% less capital invested

Capital invested by funds: $11 → $4 (-$7)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

CEROW Hedge Fund Activity: Q2 2026 in Review

1 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q2 2026, worth a combined $4 — down 64% from $11 a quarter earlier.

Fund positioning in CEROW was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held CERo Therapeutics Warrants (CEROW) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $4 of CERo Therapeutics Warrants stock for Q2 2026, down 64% quarter-over-quarter.
  • 0 funds opened new CERo Therapeutics Warrants positions in Q2 2026 and 0 closed out.

Based on aggregated 13F filings for Q2 2026.